Dopamine receptor D3 (DRD3) (DRD3)

The Dopamine receptor D3 (DRD3) is a G protein-coupled receptor (GPCR) belonging to the D2-like receptor family, primarily expressed in the limbic regions of the brain, such as the nucleus accumbens and islands of Calleja [1, 10]. It plays a pivotal role in modulating cognitive, emotional, and endocrine functions, as well as regulating the brain's reward and motivation systems [15]. DRD3 is a significant therapeutic target for neuropsychiatric and neurological conditions, including schizophrenia, bipolar disorder, Parkinson's disease, and substance use disorders [2, 9]. Drugs like aripiprazole interact with DRD3 as partial agonists, providing a stabilizing effect on dopaminergic transmission by acting as an antagonist in hyper-dopaminergic states and an agonist in hypo-dopaminergic states [4, 11]. Its restricted expression pattern compared to the D2 receptor makes it an attractive target for developing treatments with improved efficacy and reduced motor side effects [18]. Additionally, genetic variations in the DRD3 gene, such as the Ser9Gly polymorphism, have been investigated as potential biomarkers for treatment response and disease susceptibility [16, 17].

Other names

D3 dopamine receptorD3RD3DRD(3) dopamine receptorDRD3

Drugs targeting the D3 receptor act through various mechanisms including partial agonism (e.g., aripiprazole, cariprazine), full agonism (e.g., pramipexole), and antagonism (e.g., haloperidol) to modulate dopaminergic signaling pathways and stabilize neurotransmission [4, 8, 11, 13].